Semprus BioSciences is a biotech startup based in Cambridge, Massachusetts, with a mission to develop complication-free medical devices that improve long-term patient health and reduce healthcare costs. The company's innovative approach to durable surface modifications represents a significant advancement in medical device technology. Currently, Semprus BioSciences is focused on creating the first permanently dual-functional vascular access catheter with anti-colonization and anti-thrombogenic properties through a single surface modification.
Founded in 2006 and originating from the Massachusetts Institute of Technology’s Langer Lab, the company has pioneered the next-generation biofunctional surface platform. Their Semprus Surfaces™ utilize a permanent non-leaching biomaterial modification to prevent serious medical complications such as infection, blood clots, improper healing, and cell overgrowth, surpassing existing market offerings containing silver, heparin, and antibiotic coatings.
Semprus BioSciences has brought together a team of experts including scientists, industry executives, and clinical specialists to drive product development and focus on reducing complications at the nexus of the human body and implantable devices. Their work spans the biotechnology, healthcare, and medical devices industries, positioning the company at the forefront of innovation in these sectors. The company's commitment to improving patient outcomes and healthcare cost efficiencies presents compelling opportunities for investors seeking impactful contributions to the medical field.
There is no investment information
No recent news or press coverage available for Semprus BioSciences.
We care about your data, and we'd love to use cookies make your experience better.
